SAN.PA - Sanofi

Paris - Paris Delayed price. Currency in EUR
68.31
+0.64 (+0.95%)
At close: 5:37PM CEST
Stock chart is not supported by your current browser
Previous close68.25
Open68.10
Bid71.12 x 1000
Ask71.74 x 44000
Day's range67.75 - 68.71
52-week range62.88 - 89.06
Volume2,633,057
Avg. volume2,627,933
Market cap84.728B
Beta0.84
PE ratio (TTM)10.26
EPS (TTM)6.66
Earnings date31 Jul 2018
Forward dividend & yield3.03 (4.60%)
Ex-dividend date2018-05-11
1y target est77.10
  • Latecomer Sanofi looks to catch next wave of cancer therapies
    Reuters14 hours ago

    Latecomer Sanofi looks to catch next wave of cancer therapies

    Sanofi missed the boat on immune system-boosting cancer drugs. The French drugmaker has hired John Reed, the former top scientist at oncology market leader Roche to head its group research operations. Dmitri Wiederschain, head of Sanofi's immuno-oncology research, acknowledged the company had failed to capitalize on the takeoff of immunotherapy - drugs that activate the body's immune system to attack tumor cells - in the early 2010s.

  • Reuters23 hours ago

    Latecomer Sanofi looks to catch next wave of cancer therapies

    Sanofi missed the boat on immune system-boosting cancer drugs. The French drugmaker has hired John Reed, the former top scientist at oncology market leader Roche to head its group research operations. Dmitri Wiederschain, head of Sanofi's immuno-oncology research, acknowledged the company had failed to capitalise on the takeoff of immunotherapy - drugs that activate the body's immune system to attack tumour cells - in the early 2010s.

  • What Makes Sanofi (EPA:SAN) An Attractive Investment?
    Simply Wall St.2 days ago

    What Makes Sanofi (EPA:SAN) An Attractive Investment?

    Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Sanofi (ENXTPA:SAN) due to its excellent fundamentals in more than oneRead More...

  • Reuters2 days ago

    Sanofi poaches former PSA finance boss Chasseloup de Chatillon

    French drugmaker Sanofi (SASY.PA) announced it had hired Jean-Baptiste Chasseloup de Chatillon, the former chief financial officer at carmaker and Peugeot-manufacturer PSA (PEUP.PA) who had helped oversee a revival in PSA's fortunes. Sanofi said Chasseloup de Chatillon would become its executive vice-president and chief financial officer, with his position taking effect on October 1, replacing Jerome Contamine who will be retiring. "Jean-Baptiste is an experienced CFO who has been part of the impressive turnaround of PSA Group," said Sanofi chief executive Olivier Brandicourt in a statement.

  • Sanofi poaches former PSA finance boss Chasseloup de Chatillon
    Reuters2 days ago

    Sanofi poaches former PSA finance boss Chasseloup de Chatillon

    French drugmaker Sanofi (SASY.PA) announced it had hired Jean-Baptiste Chasseloup de Chatillon, the former chief financial officer at carmaker and Peugeot-manufacturer PSA (PEUP.PA) who had helped oversee a revival in PSA's fortunes. Sanofi said Chasseloup de Chatillon would become its executive vice-president and chief financial officer, with his position taking effect on October 1, replacing Jerome Contamine who will be retiring. "Jean-Baptiste is an experienced CFO who has been part of the impressive turnaround of PSA Group," said Sanofi chief executive Olivier Brandicourt in a statement.

  • GlobeNewswire2 days ago

    Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer

    June 19, 2018 - Sanofi has appointed Jean-Baptiste Chasseloup de Chatillon as Executive Vice President, Chief Financial Officer (CFO) and Member of the Executive Committee, effective October 1st 2018.  He will join Sanofi September 1st to ensure a smooth transition with Jérôme Contamine who will retire on September 30th, after more than 9 years of distinguished service at Sanofi. Mr. Chasseloup de Chatillon most recently served as Chief Financial Officer and Executive Vice-President for PSA Group.

  • Globe Newswire2 days ago

    Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer

    June 19, 2018 - Sanofi has appointed Jean-Baptiste Chasseloup de Chatillon as Executive Vice President, Chief Financial Officer (CFO) and Member of the Executive Committee, effective October 1st 2018.  He will join Sanofi September 1st to ensure a smooth transition with Jérôme Contamine who will retire on September 30th, after more than 9 years of distinguished service at Sanofi. Mr. Chasseloup de Chatillon most recently served as Chief Financial Officer and Executive Vice-President for PSA Group.

  • GlobeNewswire2 days ago

    Sanofi : Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure

    NYSE: SNY) and Ablynx announced today that Sanofi has now acquired all outstanding shares (including shares represented by American Depositary Shares ("ADSs")), warrants and convertible bonds (together, the "Securities") of Ablynx NV ("Ablynx") following the expiration of the Squeeze-out procedure.

  • Globe Newswire2 days ago

    Sanofi : Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure

    NYSE: SNY) and Ablynx announced today that Sanofi has now acquired all outstanding shares (including shares represented by American Depositary Shares ("ADSs")), warrants and convertible bonds (together, the "Securities") of Ablynx NV ("Ablynx") following the expiration of the Squeeze-out procedure.

  • Globe Newswire3 days ago

    Sanofi: Disclosure of trading in own shares

    Attachment Disclosure of trading in own shares.pdf

  • GlobeNewswire3 days ago

    Sanofi: Disclosure of trading in own shares

    Disclosure of trading in own shares This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are ...

  • EQS Group3 days ago

    EVOTEC AND SANOFI SIGN DEFINITIVE AGREEMENT TO COMBAT INFECTIOUS DISEASES

    DGAP-News: Evotec AG / Key word(s): Miscellaneous18.06.2018 / 07:00 The issuer is solely responsible for the content of this announcement. ACCELERATION OF RESEARCH AND DEVELOPMENT ("R&D") OF NOVEL ANTI-INFECTIVES 100 EMPLOYEES WILL JOIN EVOTEC SANOFI WILL LICENSE MORE THAN 10 INFECTIOUS DISEASE ("ID") R&D ASSETS SANOFI TO PROVIDE SIGNIFICANT SUPPORT TO EVOTEC INCLUDING A ONE-TIME, UPFRONT PAYMENT OF EUR 60 M TO SUPPORT PROGRESSION OF A NEXT GENERATION ANTI-INFECTIVES PORTFOLIO  

  • Sanofi Plots Cancer Comeback With First New Drug in Years
    Bloomberg8 days ago

    Sanofi Plots Cancer Comeback With First New Drug in Years

    Sanofi was a spectator during the last wave of cancer breakthroughs. The French drugmaker is counting on its first new tumor drug in seven years to help make it a contender in the next one. A treatment Sanofi is developing with Regeneron Pharmaceuticals Inc. could go on sale by the end of the year, said Joanne Lager, head of oncology development at the Paris-based company.

  • Sanofi says on track to regain solid position in cancer drugs
    Reuters8 days ago

    Sanofi says on track to regain solid position in cancer drugs

    Sanofi (SASY.PA) believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology. "We missed the immunology wagon in recent years but we are committed to catching up and we have a significant number of assets," Jorge Insuasty, Sanofi's global head of development, told journalists on Wednesday. Sanofi is working on 10 new cancer medicines.

  • GlobeNewswire8 days ago

    Sanofi : Sanofi successfully prices USD 2 billion bond issue

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)   Sanofi successfully prices USD 2 billion bond issue     Paris, France - June 13, 2018 - Sanofi has successfully priced its offering of USD 2 ...

  • Globe Newswire8 days ago

    Sanofi : Sanofi successfully prices USD 2 billion bond issue

      Press ReleaseSource: Sanofi (EURONEXT: SAN) (NYSE: SNY)   Sanofi successfully prices USD 2 billion bond issue     Paris, France - June 13, 2018 - Sanofi has successfully priced its offering of USD 2 billion of notes denominated in US dollars, across 2 tranches:   USD 1 billion fixed rate notes, due June 19, 2023, bearing interest at an annual rate of 3.375%, USD 1 billion fixed rate notes, due June 19, 2028, bearing interest at an annual rate of 3.625%. ...

  • Globe Newswire9 days ago

    Information concerning the total number of voting rights and shares

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,497,916,734 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under number 395 030 844 Date   Total number of issued shares   Number of real voting rights ...

  • GlobeNewswire9 days ago

    Information concerning the total number of voting rights and shares

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général ...

  • GlobeNewswire10 days ago

    Sanofi Launches "Action 2018", a Worldwide Employee Stock Purchase Plan

    In doing such a capital increase, Sanofi intends to better associate its employees with the future development and results of the company. On March 6, 2018­ the Board of Directors authorized an issuance of ordinary shares of Sanofi for the benefit of employees participating in the Group Savings Plan. The subscription price is €52.66.

  • Globe Newswire10 days ago

    Sanofi Launches "Action 2018", a Worldwide Employee Stock Purchase Plan

    In doing such a capital increase, Sanofi intends to better associate its employees with the future development and results of the company. On March 6, 2018­ the Board of Directors authorized an issuance of ordinary shares of Sanofi for the benefit of employees participating in the Group Savings Plan. The subscription price is €52.66.

  • The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street
    Zacks14 days ago

    The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street

    The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street

  • Top Research Reports for Mastercard, VMware & Sanofi
    Zacks15 days ago

    Top Research Reports for Mastercard, VMware & Sanofi

    Top Research Reports for Mastercard, VMware & Sanofi

  • PR Newswire16 days ago

    New England Journal of Medicine Publishes Cemiplimab Trial Results in Advanced Cutaneous Squamous Cell Carcinoma

    GUILDFORD, England , June 5, 2018 /PRNewswire/ -- - Patients treated with cemiplimab experienced robust anti-tumour effects - Data also presented today at the 2018 ASCO Annual Meeting, - Cemiplimab applications under review by regulatory authorities in the U.S. and ...

  • GlobeNewswire16 days ago

    Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)   New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma   ...

  • Globe Newswire16 days ago

    Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma

      Press ReleaseSource: Sanofi (EURONEXT: SAN) (NYSE: SNY)   New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma   Patients treated with cemiplimab experienced robust anti-tumor effects Data also presented today at the 2018 ASCO Annual Meeting Cemiplimab applications under review by regulatory authorities in the U.S. ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes